Oct 22, 2026 08:05AM
Sep 17, 2026 07:46AM
Sep 3, 2026 08:00AM
Sep 1, 2026 08:03AM
Jul 30, 2026 08:02AM
Jul 10, 2026 08:02AM
Jul 10, 2026 08:00AM MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Jul 6, 2026 09:00AM
Jun 25, 2026 08:15AM
Jun 25, 2026 08:15AM
Jun 17, 2026 08:00AM
Jun 17, 2026 08:00AM
Jun 4, 2026 08:02AM
Jun 4, 2026 08:00AM MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
May 27, 2026 08:00AM
May 27, 2026 08:00AM
May 14, 2026 08:01AM
May 14, 2026 08:00AM
May 13, 2026 08:04AM
May 13, 2026 08:00AM
Mar 23, 2026 09:03AM MIRA Pharmaceuticals reports Mira-55 shows no CNS side effects in studies
Mar 23, 2026 09:00AM
Mar 4, 2026 08:00AM
Mar 4, 2026 08:00AM
Feb 3, 2026 07:31AM
Feb 3, 2026 07:30AM
Oct 24, 2025 07:30AM
Oct 24, 2025 07:30AM MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Oct 16, 2025 04:05PM
Oct 16, 2025 07:30AM
Oct 16, 2025 07:30AM
Sep 30, 2025 07:31AM
Sep 30, 2025 07:30AM
Sep 22, 2025 08:02AM
Sep 22, 2025 08:00AM MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Sep 16, 2025 07:30AM
Sep 16, 2025 07:30AM
Sep 15, 2025 04:06PM
Sep 12, 2025 07:30AM
Sep 12, 2025 07:30AM
Aug 19, 2025 08:30AM
Aug 19, 2025 08:30AM MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
Aug 12, 2025 08:32AM
Aug 12, 2025 08:30AM
Jul 30, 2025 07:30AM
Jul 30, 2025 07:30AM
Jul 29, 2025 07:31AM
Jul 29, 2025 07:30AM
Jul 11, 2025 08:00AM MIRA reports anxiety reversal in animal study of obesity drug
Jul 11, 2025 08:00AM

472,197 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All